Potential of nanopore sequencing for rapid clinical testing in cancer predisposition genes

34 Visioni
Published
In this presentation from the Association for Molecular Pathology (AMP) 2024 Annual Meeting, hear how Dr. Stephen Murphy, Director of the Genome Analysis Core, Mayo Clinic, is exploring the potential of nanopore sequencing for rapid clinical testing in cancer predisposition genes.
Categoria
Oncology
Commenta per primo questo video.